Schizophrenia report: making sense of the latest news in schizophrenia and neurodegerative disorders

Psychiatry continues its slow transition from the neurochemical to the molecular paradigm; there was an increased search for biological markers. Connectomics aims to physically map the complete set of neural circuits that collect, process and archive information in the brain. De novo mutations could account for replenishing the genetic variants removed by natural selection. Epigenetics continue to be focused on micro ribonucleic acids (miRNAs) and their role in schizophrenia. “Jumping genes” are known to be active in various parts of our brain. Some psychotropic medications (such as valproate) are able to activate human endogenous retroviruses (HERVs). It is currently believed that minocycline has neuroprotective effects in schizophrenia and neurodegenerative diseases.